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Abstract
Background: Developing novel strategies against treatment-resistant triple negative breast cancer (TNBC) cells
remains a significant challenge. The ErbB family, including epidermal growth factor receptor (EGFR), plays key roles
in metastasis, tumorigenesis, cell proliferation, and drug resistance. Recently, these characteristics have been linked
to a small subpopulation of cells classified as cancer stem cells (CSC) which are believed to be responsible for
tumor initiation and maintenance. Ixabepilone is a new generation microtubule-stabilizing agent, which has been
expected to be more efficacious than conventional taxanes. Here we aim to investigate whether the EGFR
monoclonal antibody Cetuximab, in combination with Ixabepilone, is more effective in eliminating CSC populations
compared to chemotherapy alone in TNBC.
Methods: Representative TNBC cell lines (MDA-MB-231 and SUM159) were used to evaluate breast CSC
populations. We used fluorescence-activated cell sorter analysis (CD44+ and CD24-/low, or Aldefluor+) and a self-
renewal assay called mammosphere formation efficiency (MSFE) to measure CSC population size after treatment
with Cetuximab, or Cetuximab plus Ixabepilone in vitro.
Results: Although there was no significant decrease in cell viability, Cetuximab reduced MSFE and the CSC
population in breast cancer cells in vitro and in vivo through inhibition of autophagy. Also, SUM159 and MDA-MB-
231 orthotopic tumors demonstrated partial response to Centuximab or Ixabepilone monotherapy; however, the
effect of the combination treatment was significant only in SUM159 tumors (p <0.0001), when compared to
Ixabepilone alone.
Conclusions: Overall, our findings demonstrate that EGFR-targeted therapy by Cetuximab effectively reduces the CSC
population in TNBC tumors. However, combination therapy with Ixabepilone may be effective only in a small subset of
TNBCs, warranting further investigation of alternative approaches to target multiple pathways for TNBC treatment.
Background
Triple-negative breast cancer (TNBC), which accounts
for 20 % of all breast cancers, is characterized by the ab-
sence of estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2
(HER2) expression. They are histologically high grade,
aggressive, and lethal tumor types that lack targeted
therapeutic options. Patients with TNBC are associated
with relatively poor prognosis and are at a significant
risk of relapse and frequent metastases [1, 2]. Triple-
negative and basal-like breast cancers display a similar
profile of cell-surface markers of breast cancer stem cells
(CSCs) [3]. CSCs are defined as rare tumor cells that are
capable of self-renewal and give rise to multipotent
progenitor cells, which ultimately differentiate into all
cell types within the tumor [4–6]. CSCs have been
identified by cell sorting technologies using various
surface markers in acute myeloid leukemia and solid
tumors, including breast tumors [7]. Studying tumori-
genic cells separated in vitro, from malignant human
breast cancer-derived pleural effusions, Al Hajj and
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colleagues isolated a cell population characterized by
high CD44 expression and low or undetectable levels of
CD24 (CD44+/CD24−/low). These cells had classic features
of bona fide stem cells, including the capacity for self-
renewal and generation of heterogeneous progeny [8].
This subpopulation can form mammospheres in vitro and
were shown to be enriched for tumorigenic cells by their
ability to form xenograft tumors in immunocompromised
mice [8]. Ginestier et al. demonstrated that aldehyde
dehydrogenase 1 is an alternative marker for breast
CSCs [8]. We have recently shown that CD44+/CD24−/low
and ALDH+ phenotypes reflect different epithelial-
mesenchymal transition states in CSCs [9]. Identification
of breast CSCs from tumor samples or breast cancer cell
lines has been based mainly on CD44+/CD24−/low or
ALDH+ phenotypes. We have previously reported that
breast CSCs are a subpopulation of cells within the pri-
mary tumor responsible for tumor initiation and metasta-
ses, and are associated with resistance to chemotherapy in
human breast cancers following neoadjuvant chemother-
apy [10]. In addition, it has been shown that epidermal
growth factor receptor (EGFR) signaling may be required
for cancer self-renewal [11]. EGFR is more commonly
overexpressed in TNBC than in other breast cancer sub-
types [12, 13]. Also, TNBC can be classified as basal type
cancer defined by EGFR and cytokeratin 5/6 staining.
Ixabepilone is a new-generation microtubule-stabilizing
agent and has more efficacious anti-tumor effects than tax-
anes [14, 15]. It is an analog of epothilone B, a naturally oc-
curring microtubule stabilizer with very high cytotoxic
activities against a wide range of tumor types, including
drug-resistant tumors. For example, anthracycline- and
taxane-resistant metastatic breast cancers (MBCs) are
known to be highly sensitive to Ixabepilone as a single agent
or in combination with Capecitabine [13]. Importantly,
significant anticancer activity was seen in ER, PR, HER2
negative TNBC patients with MBC. This is consistent with
the preclinical activity of Ixabepilone against human can-
cer cell lines resistant to taxanes and other agents [16].
Combination therapy is a mainstay of anticancer
treatment, with optimal combinations producing syn-
ergistic antitumor responses. This is achieved by com-
bining agents with established safety profiles and non-
overlapping mechanisms of action. Thus, this study
seeks to evaluate the combination therapy of combining
Cetuximab and Ixabepilone, which might be more effect-
ive at targeting cancer stem cells than other antitubulins,
as a possible way to increase antitumor activity. In the
present study, we investigated whether the breast CSC
population enriched for tumorigenic CD44+CD24−/low
cells could be eradicated when treated with Cetuximab
and Ixabepilone, as opposed to chemotherapy alone, in
TNBC xenografts. Our findings suggest that Ixabepilone
produces therapeutic synergism with Cetuximab only in a
small subset of TNBCs and provides additional evidence
that clinical trials using Cetuximab in combination with
Ixabepilone should be applied with caution.
Methods
Cell proliferation and viability measurements (WST-1 assay)
TNBC cell lines MDA-MB-231 and SUM159 were pur-
chased from American Type Culture Collection (ATCC),
Manassas, VA, USA, and from Asterand, Detroit, MI, USA,
These cell lines were chosen based on their high expression
of epithelial-mesenchymal transition markers (EMT),
metastatic properties, and percentage of CD44+ /CD24-
cells. Both cell lines were grown in DMEM (Invitrogen,
Carlsbad, CA) with 10 % fetal bovine serum (Cellgro, Ma-
nassas, VA) and 1 % penicillin/streptomycin. WST-1 assay
was performed using Premixed WST-1 Cell Proliferation
Reagent (Clontech, Mountain View, CA) according to the
manufacturer’s protocol to access cell viability. Cells were
seeded into 96-well tissue culture plates at the concentra-
tion of 2,000 cells/well and incubated at different concen-
trations of Cetuximab (Erbitux, Bristol Myers Squibb, NJ)
(0.001–100 μg/ml), Cetuximab (1 nM–100 uM) or in com-
bination with Ixabepilone (Ixampra, Bristol Myers Squibb,
NJ) for 72 h. Cell viability was analyzed indirectly by meas-
uring formazan formation by mitochondrial dehydroge-
nases in viable cells. The absorbance was measured using a
multiwall scanning spectrophotometer (Infinite M200 pro,
Tecan, Switzerland) at 440 nm (measurement wavelength)
and 600 nm (reference wavelength).
Fluorescence-activated cell sorting (FACS) for
CD44+CD24−/low cell isolation
To analyze CD44+/CD24-/low cells, approximately 106 cells
were resuspended in Hank’s balanced salt solution (HBSS)
supplemented with 2 % fetal bovine serum, mixed, and in-
cubated for 15 minutes at 4 °C with mouse monoclonal
anti-CD44-APC (0.6 μg/100 μl/test) and anti-CD24–PE
(4 μg/100 μl /test) (BD Pharmingen, San Jose, CA, USA)
according to the manufacturer’s instructions. The cells were
then washed and resuspended in HBSS (Invitrogen, Carls-
bad, CA, USA) supplemented with 1 M HEPES. Propidium
iodide (PI) was added to exclude dead cells before FACS
analysis using BD LSRII flow cytometry (BD Bioscience,
San Jose, CA, USA). Only live and single cell populations
were gated out for population analysis using a PI gate and
side and forward scatter gates. Negative and positive con-
trols were stained with antibodies of isotype control, PE
(phycoerythrin) positive control, APC (allophycocyanin)
positive control, or fluorescein isothiocyanate (FITC) posi-
tive control. All experiments were repeated three times.
Aldefluor (ALDF) assay
The Aldefluor assay was performed as described by the
manufacturer (Stem cell technology, BC, Canada). Briefly,
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5 × 105 cells were incubated for 45 minutes at 37 °C with
ALDF cocktail (ALDF reagent; 2.5 μl, ALDF Buffer;
500 μl/test). After washing the ALDF buffer, the cells
were rinsed and resuspended in HBSS + 1 M HEPES.
For xenograft tumors, cells were additionally stained
with anti-H2Kd-PE (2.5 μl/100 μl/test) antibodies on
ice for 15 minutes to exclude mouse components. We
used cells stained with DEAB cocktail (DEAB reagent;
5 μl ALDF reagent; 2.5 μl ALDF buffer; 500 μl/test)
as negative controls.
Mammosphere-forming assay
Mammosphere-forming efficiency (MSFE) was measured
by counting spheres as previously described [17, 18]. In
brief, cancer cells (5,000 cells/ml) were cultured for 72 h
in ultralow attachment 24-well plates (Corning Costar
Co., MA, USA) with the mammosphere culture medium
Plus (MEGM+, Lonza, Switzerland) containing 20 ng/ml
of bFGF (Invitrogen, Carlsbad, CA, USA), 20 ng/ml of
EGF (Invitrogen), 4 μg/ml of heparin (StemCell Tech-
nologies, BC, Canada), and B27 supplement (Invitrogen).
Cells were treated at the time of cell seeding with Cetux-
imab, Ixabepilone, or the combination at the indicated
concentrations. Mammospheres were counted using the
Gel Counter (Optronix, UK) and GelCount software. To
calculate the MSFE, the following formula was used:
MSFE %ð Þ ¼ Total number of spheres  100ð Þ
 Total number cells seeded
Each experiment was repeated at least three times with
six replicates for each treatment group.
Animal experiments
All animal protocols were reviewed and approved by
the Animal Protocol Review Committee at Houston
Methodist Research Institute (Houston, TX, USA).
MDA-MB-231 or SUM159 cells (2 × 106 cells/100 ml)
were injected orthotopically in female immunocom-
promised severe combined immunodeficiency (SCID)/
Beige mice (Charles River Laboratories, Wilmington,
MA, USA). After tumors reached 5–8 mm in diameter,
mice were randomly grouped based on tumor sizes and
injected intravenously with (A) control, intravenous (i.v.)
PBS, (B) Cetuximab, i.v. (4 mg/kg/weekly) (C) Ixabepilone,
intraperitoneal (i.p.) (10 mg/kg/weekly), (D) Cetuximab,
i.v. + Ixabepilone, i.p. (equivalent dose/weekly). Tumor di-
ameters and body weights were recorded twice per week,
and mice were euthanized at the end of treatment or
when the recurrent tumor size reached the basal level.
The tumors were then excised, minced, and digested in
mammary epithelial growth medium (MEGM) with 200–
250 U/ml of Collagenase type III (Worthington, NJ) and
0.8 units/ml of Dispase (Worthington, NJ) in a shaking
incubator at 37 °C for 1.5 h. The samples were filtered,
subjected to hypotonic shock (9 ml of sterile H2O for 10
seconds followed with 1 ml of 10 ×HBSS) to lyse red
blood cells, washed with HBSS, and finally re-filtered for
single cells using 40-μm pore filters. To analyze MSFE,
cells (20,000 cells/ml) were plated in the ultralow attach-
ment, as described above, for 2 weeks.
Western blot assay
Western blotting was performed as previously described
[17]. Briefly, cells were lysed with 1X Cell Lysis Buffer
(Cell Signaling Tech., Danvers, MA, USA). After meas-
uring the protein concentration using a Pierce BCA pro-
tein assay kit (Thermo Fisher Scientific Inc, Waltham,
MA, USA), a total of 300 μg of protein extract from each
sample was mixed with 4 × sample buffer (Bio-Rad,
Hercules, CA, USA) containing 5 % β-mercaptoethanol
(Sigma, St. Louis, MO, USA). Samples (30 μg/well) were
loaded onto a 4–20 % SDS-PAGE gel and transferred to
nitrocellulose membranes (Bio-Rad). All antibodies were
purchased from Cell Signaling Technology: phospho-
EGF receptor (Tyr1068) antibody, EGF receptor anti-
body (1 F4), phospho-AKT (Ser473) antibody, AKT
antibody, phospho-extracellular signal-regulated kinase
(ERK)1/2 antibody, ERK1/2 antibody, p62, LC3b, and
β-Actin.
Statistical analyses
All quantitative parameters are presented as mean
with standard deviation, and all results are expressed
as mean ± standard error of the mean (SEM) for in
vivo experiments. In vitro (WST-1 assay, flow cytome-
try, or mammosphere-forming efficiency) results were
analyzed using Student’s t test, and the Mann–Whit-
ney U test for unpaired samples. In vivo data were
statistically evaluated by means of two-way analysis of
variance (ANOVA). Significant treatment effects were
subsequently delineated by using Dunnett’s post hoc
test. Statistical significance was assumed for p <0.05.
Results
Cell viability of triple-negative cell lines treated with
Cetuximab and Ixabepilone
Cell viability was analyzed using the WST-1 assays of
Cetuximab or Ixabepilone in the TNBC cell lines MDA-
MB-231 and SUM159 (Fig. 1). The viability of these cells
did not change with increasing doses of Cetuximab
(Fig. 1a and b). On the other hand, both cell lines were
sensitive to Ixabepilone in a statistically significant
dose-dependent manner (p <0.01) (Fig. 1c and d).
The inhibitory concentration (IC)50 was 10 ± 3 nM for
MDA-MB-231 cells and 8 ± 2 nM for SUM159 cells.
We found that Ixabepilone was the main contributor
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to cytotoxicity in the combination regimen of Cetuximab
and Ixabepilone (data not shown).
Breast CSCs are sensitive to Cetuximab
We evaluated the effects of Cetuximab on the CSC
population by analyzing CD44+/CD24-/low, or ALDF+
populations using FACS. The tested doses of Cetuximab
were 10, 30, and 50 μg/ml. After treatment with
Cetuximab for 3 days, a dose-dependent reduction in
the CD44+/CD24-/low population of MDA-MB-231
cells was observed and the reduction was highest at a
dose of 50 μg/ml, from 89.8 % to 35.8 % (p <0.01)
(Fig. 2a). Cetuximab also reduced the ALDF+ population
dose-dependently, with a maximum decrease from 2.2 to
0.4 % (p <0.01) at 50 μg/ml of Cetuximab (Fig. 2b). Simi-
larly, the highest concentration of Cetuximab reduced the
ALDF+ population from 2.5 to 0.7 % (p <0.01) in SUM159
cells in a dose-dependent manner (Fig. 2c).
Cetuximab inhibits clonogenicity of TNBC cells
Mammosphere-forming assays were performed to evalu-
ate the effects of Cetuximab alone or in combination
with Ixabepilone on MSFE of TNBC cells by measuring
MSFE. The results showed that Cetuximab alone de-
creased MSFE in MDA-MB-231 cells from 0.24 to 0.13 %
(p <0.05) and in SUM159 cells from 0.28 % to 0.16 %,
(p <0.05) (Fig. 3a and b). Ixabepilone monotherapy
had no effect on MSFE in either cell line. We also found
that the combination therapy significantly reduced the
MSFE of MDA-MB-231 cells at the 50 μg/ml dose of
Cetuximab (the mean MSFE at Ixabepilone 5 nM of 0.21 %
versus Ixabepilone 5 nM+Cetuximab 50 μg/ml of 0.10 %,
p <0.05) (Fig. 3a). The combination treatment resulted
in a reduction in MSFE for SUM159 cells, but the change
was not statistically significant (mean at Ixabepilone 5 nM
of 0.30 % versus Ixabepilone 5 nM+Cetuximab 50 μg/ml
of 0.20 %, p >0.05) (Fig. 3b). These results suggest that the
EGFR signaling pathway may be critical for clonal expan-
sion of CSCs.
Tumor growth of TNBC xenografts with Cetuximab
treatment
We established human breast cancer cell xenografts in
immunocompromised SCID/Beige mice using MDA-
MB-231 or SUM159, and divided them into four groups
(control, Cetuximab, Ixabepilone, and combination). As
shown in Fig. 4, Cetuximab therapy alone was effective in
both MDA-MB-231 (tumor doubling time, TDT = 14 ± 3
days, p <0.05) and SUM159 (TDT = 30 ± 10 days, p <0.05)
xenografts compared to control (TDT = 16 ± 3 days).
In addition, the combined therapy induced a dramatic
reduction in the tumor growth of SUM159 xenografts
Fig. 1 The effect of Ixabepilone or Cetuximab on cell viability of triple-negative breast cancer cell lines with WST-1. WST-1 proliferation assay of
MDA-MB-231 cells and SUM159 cells treated with Cetuximab (MDA-MB-231 cells (a) SUM159 cells (b)), or Ixabepilone (MDA-MB-231 cells (c),
SUM159 cells (d)). The data for each cell line are mean ± standard deviation obtained from three independent experiments
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(TDT = 110 ± 25 days, p <0.001) compared to Ixabepi-
lone alone (TDT = 25 ± 8 days) (Fig. 4b). The combin-
ation treatment in MDA-MB-231 xenografts caused a
decrease in tumor growth, but was not statistically
significant (Fig. 4a). Also, the combination treatment
was not toxic, and the weight curves of the combined
treatment groups were similar to other groups in the
xenografts (data not shown). These results suggest
that Cetuximab is effective against CSCs, and treating
TNBC xenografts with the combination therapy did
not result in additive toxicity.
Effects of Cetuximab treatment on breast CSCs in TNBC
xenografts
To evaluate the effect of Cetuximab, Ixabepilone, and
combined treatment on breast CSCs in MDA-MB-231
and SUM159 xenografts, we performed both FACS ana-
lysis and MSFE assays of xenograft tumor specimens
taken after treatment. In MDA-MB-231 xenograft tumors,
the mean percentage of CD44+/CD24-/low cells decreased
after treatment with Cetuximab (31.8 %, p <0.05) or the
combination treatment (29.3 %, p <0.05) compared to
control (56.1 %) (Fig. 5a). Of note, ALDF + cells were not
identified in most of the MDA-MB-231 xenograft tumors
(Fig. 5e). The MSFE of MDA-MB231 xenografts decreased
after Cetuximab treatment (mean = 2.9 %, p <0.01) or
combination (mean = 0.8 %, p <0.05) compared to control
(mean = 4.9 %) (Fig. 5c). On the other hand, the mean
ALDF + percentage decreased by the combination treat-
ment in SUM159 xenograft tumors (5.3 %, p = 0.05)
compared to control (12.4 %) (Fig. 5b). However,
CD44+/CD24-/low cells were not identified in most
Fig. 2 FACS analysis for double staining of CD44+/CD24-/low and Aldefluor (ALDF) in MDA-MB-231, or Aldefluor in SUM159. Representative results
of FACS analysis identified by CD44+/CD24-/low in MDA-MB-231 (a), Aldefluor + in MDA-MB-231 (b), and Aldefluor + in SUM159 (c) treated with different
doses of Cetuximab (10 μg/ml, 30 μg/ml, or 50 μg/ml) for 3 days. Proportion (%) of CD44+/CD24-/low or Aldefluor + cells were determined
and represented by the average of FACS analysis performed in triplicate
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SUM159 xenograft tumors. Cetuximab treatment de-
creased the MSFE of SUM159 xenografts, but not to
statistical significance (Fig. 5d). These results show
that Cetuximab has the ability to decrease CSC popu-
lations in TNBC xenograft tumors.
Cetuximab-treated tumors have decreased autophagy
(LC3b, p62 and autophagosomes)
To determine whether Cetuximab targets the EGFR sig-
naling pathway and autophagy, we performed immuno-
blotting to determine the expression levels of EGFR,
phospho-EGFR, LC3b-I and II, and p62 against the ef-
fects of Cetuximab, Ixabepilone, and the combination
treatment in MDA-MB-231 and SUM159 cells (Add-
itional file 1: Figure S1). Western blot analysis revealed
that Ixabepilone treatment increased the expression of
several proteins including EGFR, phospho-EGFR,
phospho-AKT(473), and phospho-ERK1/2 in both cell
lines. Cetuximab reduced phospho-AKT(473) and
phospho-ERK1/2, which are downstream of EGFR in
the signaling pathway. In addition, Cetuximab and es-
pecially the combination treatment downregulated the
autophagy markers p62 and LC3b-II in MDA-MB-231
and SUM159 cells compared to control or Ixabepilone.
Although Ixabepilone increased p62 expression, Ixabe-
pilone either reduced or had no effect on the basal
Fig. 3 Mammosphere-forming efficiency of MDA-MB-231 and SUM159 cells treated with Cetuximab +/- Ixabepilone. Mammosphere formation
(%) of MDA-MB-231 (a) and SUM159 (b) cells was compared between control (no treatment) and Cetuximab treatment at concentrations of 10
μg/ml, 30 μg/ml, 50 μg/ml or between Ixabepilone (5 nM) and Ixabepilone (5 nM) + Cetuximab treatment at 10 μg/ml, 30 μg/ml, 50 μg/
ml. The Mann–Whitney U test was used to determine the p values. Data represent the mean of three independent experiments. N.S. not significant
Fig. 4 MDA-MB-231 and SUM159 tumor models of xenograft mice treated with Cetuximab, Ixabepilone, and combination. Means of the percentage
in tumor volume of control (intravenous (i.v.), PBS), Cetuximab (i.v., 4 mg/kg/weekly), Ixabepilone (intraperitoneal (i.p.), 10 mg/kg/weekly), or
combination (Cetuximab, i.v + Ixabepilone, i.p (equivalent dose/weekly))-treated MDA-MB231 (a) or SUM159 (b) tumors in SCID/Beige mice
were plotted as a function of time. Two-way analysis of variance with Bonferroni post-hoc test was used to determine significant differences
among groups and p <0.05 was considered to be statistically significant
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levels of LC3b-II in MDA-MB-231 and SUM159 cells,
respectively. These results suggest that Ixabepilone
upregulated autophagy. Together, these findings pro-
vide strong evidence that Cetuximab inhibits the Akt
and Erk1/2 pathways, resulting in downregulation of
p62 and LC3b. Moreover, the combination treatment
decreased autophagy by inhibiting Ixabeplione-
induced EFGR activation.
Discussion
Tumorigenic CSCs are intrinsically resistant to conven-
tional chemotherapy and have unique properties includ-
ing enhanced self-renewal and increased propensity for
tumor formation [10, 19]. CSCs have been identified
in various tumors including those of the breast, and
they are particularly enriched in the basal-like and
claudin-low subtypes of breast cancer. Cell lines
representing the basal-like subtype (SUM159) and
claudin-low subtype (MDA-MB-231) of breast cancer
were utilized to study the anti-CSC effects of Cetuximab
in combination with Ixabepilone. Our results indicate that
Cetuximab alone or in combination with Ixabepilone
significantly inhibited tumor growth and reduced
CD44+/CD24-/low CSC population in vitro and in vivo.
However, the efficacy of the combination therapy varied in
the two in vivo models compared to Ixabepilone mono-
therapy in that the effects of the combination were far
greater in SUM159 tumors than in MDA-MB-231 tumors.
Trédan et al. [20] recently reported that the clinical effect-
iveness of the Cetuximab and Ixabepilone combination
was similar to that of Ixabepilone monotherapy in a
first-line treatment of locally advanced or metastatic
Fig. 5 FACS analysis and mammosphere-forming efficiency in MDA-MB-231 or SUM159 xenografts. Representative results of CD44+/CD24-/low
population (%) in MDA-MB-231 xenografts (a), Aldefluor + population (%) in SUM159 xenografts (b), mammosphere formation (%) in MDA-MB-231
xenografts (c), or mammosphere formation (%) in SUM159 xenografts (d). CD44+/CD24-/low population (%) and mammosphere formation (%) of
MDA-MB-231 xenografts were reduced by Cetuximab alone or combination treatment. Aldefluor + population (%) in SUM159 xenografts de-
creased by combination treatment when compared to control. CD44+/CD24- cells (%) in SUM159 xenografts were extremely low in proportion
and are not represented in the figure. N.S. not significant
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TNBC. Similarly, the results of two additional inde-
pendent randomized phase II clinical trials, evaluating
the effects of Cetuximab in combination with either
cisplatin [21] or carboplatin [22], were similar to the
clinical trial with Cetuximab and Ixabepilone. Carley
et al. [22] separated patients into two groups, non-re-
sponders and responders, to the combination therapy by
analyzing signaling signatures in post-treatment speci-
mens. This revealed that low KRAS-amplicon expression
was associated with a better response to the combination
therapy of Cetuximab and carboplatin. In agreement with
the results of the previous clinical trials, our data using
two animal models reflect the disputed sensitivity of
TNBC to Cetuximab in combination with chemotherapy.
According to the Pietenpol TNBC classification [23], both
cell lines are classified as mesenchymal-like. However,
SUM159 cells have an H-Ras mutation and exhibit ana-
plastic carcinoma histology while MDA-MB-231 cells
have a K-Ras mutation and invasive ductal carcinoma hist-
ology. These features may have contributed to the min-
imal response observed in MDA-MB-231 tumor models
with the combination treatment. Additionally, differences
in sensitivity to Ixabepilone may be another possible con-
tributor to the bifurcated drug response with combination
therapy, as our data indicate that SUM159 cells are more
sensitive to Ixabepilone than MDA-MB-231 cells both in
vitro and in vivo.
It was intriguing to observe that Cetuximab was not
cytotoxic, but reduced CSCs in both cell lines in vitro
and in vivo. This result is in agreement with previous re-
ports that Cetuximab has little impact on cell viability
[24, 25]. We speculate that the EGFR signaling pathway
may be critical to maintain the stemness of CSCs, and
that loss of EGFR signaling may induce differentiation of
the CSCs to a non-CSC population. This notion is sup-
ported by data from Harrison et al. [26], Yang et al. [27],
and Gillian et al. [28], showing that EGFR signaling is
critical for CSC stemness in human and murine breast
CSCs. Previously, we reported that the treatment of
patients with HER2-positive tumors using lapatinib (an
EGFR/HER2 inhibitor) led to a statistically non-significant
decrease in the percentage of CD44+/CD24-/low cells,
and also a significant decrease in MSFE [29]. Despite
effective targeting of the CSC population, our data
suggested that inhibiting EGFR by Cetuximab in com-
bination with Ixabepilone did not have significant
anti-cancer effects in TNBC tumors. We hypothesize
that either tumor heterogeneity or the development of
compensatory mechanisms may have played a role in the
minimal response to the Cetuximab and Ixabepilone com-
bination. Supporting this hypothesis, Jacobsen et al. [30]
recently showed that targeting EGFR can trigger compen-
satory activation of other ErbB family receptors, HER2
and/or HER3, and that simultaneous inhibition of EGFR,
ErbB2 and ErbB3 effectively overcame tumor heterogen-
eity and plasticity.
Previously, we reported that the CSC population in-
creases after chemotherapy in both clinical and preclin-
ical settings [17, 29, 31], and that autophagy is the
underlying mechanism for the survival and maintenance
of the CSC population [17]. In this report, we found that
Ixabepilone treatment increased autophagy with a con-
comitant increase in EGFR signaling, while Cetuximab
inhibited autophagy by reducing the expression of the
autophagy markers p62 and LC3b. Therefore, we specu-
late that the inhibition of autophagy by Cetuximab may
have played a role in reducing the CSC population.
However, Li et al. have also shown that Cetuximab in-
duces autophagy in A431 human vulvar squamous car-
cinoma cells, DiFi colorectal adenocarcinoma cancer
cells, and HCC827 human non-small cell lung cancer
cells by downregulating HIF-1α and Bcl-2 and activating
the beclin-1/hVps34 complex [32]. Thus, the regulation
of autophagy by Cetuximab may differ depending on the
type of cancer being studied.
Conclusions
These studies show that EGFR-targeted therapy effect-
ively reduces CSC populations in SUM159 and MDA-
MB-231 tumors and tumor growth in vivo. However,
our in vivo data suggest that the effects of the combin-
ation therapy of Cetuximab and Ixabepilone may vary
based on the TNBC subtype and support recent clinical
trial results. Thus, EGFR-targeted therapy should be
considered with caution for TNBC patients, and further
investigation of TNBC subtypes, using patient-derived
xenograft TNBC models [33, 34], may help to determine
TNBC patient groups suitable for the combination
therapy.
Additional file
Additional file 1: Figure S1. Cetuximab treatment reduces autophagy.
Western blot showed effects of cetuximab, ixabepilone, and combination
(cetuximab + ixabepilone) treatment in MDA-MB-231 and SUM159 cells.
Immunoblots were probed with antibodies against pEGFR, total EGFR,
pARK, total ARK, p62, LC3b, pERK1/2, total ERK1/2, and b-Actin. Protein
expression has been quantitated and normalized against the loading
control, and the results of median of three replicates are represented in
the table. (TIF 7 MB)
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